Mechanistic PBPK Modelling to Predict the Advantage of the Salt Form of a Drug When Dosed with Acid Reducing Agents by Siri Kalyan Chirumamilla, Venkatesh Teja Banala, Masoud Jamei, David B. Turner

Connect to this object online.

Physiologically Based Biopharmaceutics Model (PBBM) of Minimally Absorbed Locally Acting Drugs in the Gastrointestinal Tract-Case Study: Tenapanor by Konstantinos Stamatopoulos, Nena Mistry, Nikoletta Fotaki, David B. Turner, Brandon Swift

Connect to this object online.

Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug by Farzaneh Salem, Ali Nimavardi, Jennypher Mudunuru, Debra Tompson, Jackie Bloomer, David B. Turner, Kunal S. Taskar

Connect to this object online.

Developing Clinically Relevant Dissolution Specifications (CRDSs) for Oral Drug Products: Virtual Webinar Series by Mark McAllister, Talia Flanagan, Susan Cole, Andreas Abend, Evangelos Kotzagiorgis, Jobst Limberg, Heather Mead, Victor Mangas-Sanjuan, Paul A. Dickinson, Andrea Moir, Xavier Pepin, Diansong Zhou, Christophe Tistaert, Aristides Dokoumetzidis, Om Anand, Maxime Le Merdy, David B. Turner, Brendan T. Griffin, Adam Darwich, Jennifer Dressman, Claire Mackie

Connect to this object online.